Oral prenylation inhibition with lonafarnib in chronic hepatitis D infection: a proof-of-concept randomised, double-blind, placebo-controlled phase 2A trialChristopher Koh, Theo Heller, Mark A. Winters et al.|The Lancet Infectious Diseases|2015Cited by 262
Modeling of patient virus titers suggests that availability of a vaccine could reduce hepatitis C virus transmission among injecting drug usersMarian Major, Harel Dahari, Alexander Gutfraind et al.|Science Translational Medicine|2018Cited by 46
Advances and Challenges in Managing Hepatitis D Virus: Evolving StrategiesHarish Gopalakrishna, Theo Heller, Christopher Koh et al.|Current Hepatology Reports|2024Cited by 15